Status:
COMPLETED
Safety & Efficacy of Nuberol Forte® in Pain Management
Lead Sponsor:
The Searle Company Limited Pakistan
Conditions:
Musculoskeletal Disorder
Pain Management
Eligibility:
All Genders
18-70 years
Brief Summary
The global prevalence of Musculoskeletal disorders (MSD) ranges from 14% to as high as 42%. In addition WHO also estimates that 40% of people over the age of 60 years suffer from MSD and about 80% of ...
Detailed Description
The management of musculoskeletal pain is complex therefore plethora of treatment options are available include non-pharmacological treatments , complementary therapies, and pharmacological interventi...
Eligibility Criteria
Inclusion
- Patient with a clinical history of painful musculoskeletal disorder from last 1 year
- Patient aged ≥18 and ≤70 years inclusive of either sex
- Patient with ability to understand and sign written informed consent form.
Exclusion
- Known hypersensitivity to Nuberol Forte product, the metabolites, or formulation excipients.
- Patients with Glaucoma, prostatic hypertrophy or obstruction at the bladder neck, myasthenia gravis, oesophageal spasm and pyloric or duodenal obstruction.
- Treated with Nuberol Forte to evaluate safety as per approved prescribing information for Nuberol Forte in Pakistan.
- Pregnant (assesed on LMP) or breast feeding women (assessed on interview).
Key Trial Info
Start Date :
November 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
399 Patients enrolled
Trial Details
Trial ID
NCT04765787
Start Date
November 25 2020
End Date
August 1 2021
Last Update
November 10 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Liaquat National Hospital
Karachi, Sindh, Pakistan
2
Medicare Hospital
Karachi, Sindh, Pakistan
3
Patel Hospital
Karachi, Sindh, Pakistan